Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Onyx Biotec Limited IPO
Onyx Biotec Ltd
₹1,16,000 /2000 sharesMinimum Investment
Onyx Biotec Limited IPO Listing Details
| Listed On | Issue Price | Listing Price | Listing Gains |
|---|---|---|---|
| -- | ₹61.00 | ₹54.05 | -₹6.95 (11.39%) |
Onyx Biotec Limited IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 13 Nov ‘24 - 18 Nov ‘24 | ₹1,16,000 | 2,000 | ₹58 - ₹61 |
| Issue Size | IPO Doc |
|---|---|
| 29.34Cr | RHP PDF |
Subscription rate
As of 18 Nov'24, 04:00 PM
| Qualified Institutional Buyers | 0.00x |
| Non-Institutional Investor | 0.00x |
| Retail Individual Investor | 0.00x |
| Total | 9.11x |
About Onyx Biotec Limited
Founded in
2005
Managing director
Mr. Sanjay Jain
Parent organisation
Onyx Biotec Ltd
Strengths & Financials of Onyx Biotec Limited
Strengths
Risks
Onyx Biotec has over a decade of experience in sterile pharmaceutical manufacturing. The company has built a strong reputation among leading Indian and multinational pharmaceutical companies.
The company operates two manufacturing units in Himachal Pradesh, a major pharmaceutical hub, benefiting from access to skilled labour and cost-effective operations.
Onyx Biotec is ISO 9001:2015 certified for quality management systems and ISO 14001:2015 certified for environmental management systems.
The company claims to have a client base of over 100 pharmaceutical companies, with repeat business from 35 clients in recent years.
Onyx Biotec’s manufacturing facilities are WHO-GMP certified. Regular audits and inspections by clients and regulatory bodies are conducted to ensure continued compliance and uphold production quality.
Onyx Biotec has two manufacturing facilities, and both are located in Solan, Himachal Pradesh. Due to this concentration of the units, any change in the business environment of this region can negatively impact the company’s prospects.
The company could lose contracts in the case of any manufacturing or quality control concerns or inability to deliver products on time. This could have an adverse impact on the company’s business.
The company relies on domestic and international third-party suppliers for raw materials. The amounts expended on the top five suppliers stood at Rs 4.92 crore (75.47%), Rs 27.09 crore (70.34%), Rs 18.69 crore (76.91%), and Rs 20.64 crore (78.73%) for the period ending May 31, 2024, FY24, FY23, and FY22, respectively. Any disruption in supply from them could negatively impact the company’s business operations.
The top 10 customers of Onyx Biotec contributed Rs 8.65 crore (82.13%), Rs 38.25 crore (71.16%), Rs 37.31 crore (94.48%), and Rs 42.16 crore (93.98%) to revenue from operations for the period ending May 2024, FY24, FY23, and FY22, respectively. Any failure to retain these key customers or a loss of business from them could adversely affect the company’s business prospects.
The company has experienced negative cash flows in recent years. Any repeat of this in the future could hurt its growth, impacting its overall financial health.
As of May 31, 2024, Onyx Biotec had outstanding financial indebtedness of Rs 2.82 crore in unsecured loans and Rs 28.74 crore in secured loans. Any failure to service or repay these loans could adversely impact the company’s operations and financial position.
Onyx Biotec Limited Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Onyx Biotec Limited IPO
| Apply as | Price band | Apply Range |
|---|---|---|
| Regular | ₹58 - 61 | ₹2 - 5 Lakh |
| High Networth Individual | ₹58 - 61 | ₹2 - 5 Lakh |
For Onyx Biotec Limited IPO, eligible investors can apply as Regular.